Articles

A phase 1b study showed that isatuximab is clinically active in patients with relapsed/refractory multiple myeloma.

The combination of bendamustine and pomalidomide with dexamethasone shows promise in patients with relapsed/refractory multiple myeloma (RRMM).

The DSMM XIV study highlights the efficacy of bortezomib versus doxorubicin in combination with lenalidomide and dexamethasone prior to stem-cell transplant in patients with newly diagnosed multiple myeloma.

The Myeloma XI Study analyzed lenalidomide induction and maintenance therapy in transplant-eligible patients with myeloma.

Data from the Connect MM Registry show poor survival outcomes in African American patients with newly diagnosed multiple myeloma (NDMM) and t(11;14) mutation.

Results from the KEYNOTE-023 trial show that the combination of pembrolizumab plus lenalidomide and low-dose dexamethasone is efficacious in patients with relapsed/refractory multiple myeloma (RRMM).

Chimeric antigen receptor (CAR) T-cell therapy with bb2121 shows a promising new treatment paradigm in patients with relapsed/refractory multiple myeloma (RRMM).

Pomalidomide plus low-dose dexamethasone used as third-line therapy improves survival outcomes in patients with relapsed/refractory multiple myeloma (RRMM).

This phase 3 study compared lenalidomide maintenance versus placebo after stem-cell transplant in patients with newly diagnosed multiple myeloma, adjusting overall survival (OS) and progression-free survival (PFS) for treatment crossover.

Insights from the Connect MM Registry show that lenalidomide maintenance therapy after autologous stem-cell transplant (ASCT) significantly improves progression-free survival and overall survival in patients with newly diagnosed multiple myeloma (NDMM).